Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2
暂无分享,去创建一个
S. Jagannath | D. Madduri | S. Parekh | L. Isola | A. Chari | J. Richter | L. Sanchez | H. Cho | D. Verina | Kevin Barley | D. Catamero | Talia Goldstein | Amishi Dhadwal | K. Zarychta | Gillian Sanchez | E. Florendo | Moon-hee Yum | Lisa La | Jude Gullie | E. Chan